Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Cattrini

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Immunotherapy|November 22, 2021
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysisSebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, et al.
Cancers|September 25, 2019
Current Treatment Options for Metastatic Hormone-Sensitive Prostate CancerCarlo Cattrini, Elena Castro, Rebeca Lozano, et al.
Translational Oncology|May 17, 2020
Integrative Analysis of Periostin in Primary and Advanced Prostate CancerCarlo Cattrini, Paola Barboro, Alessandra Rubagotti, et al.
Anti-Cancer Drugs|July 12, 2016
Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectivesCarlo Messina, Giulia Buzzatti, Chiara Dellepiane, et al.
Breast Cancer Research and Treatment|July 29, 2018
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trialsCarlo Messina, Carlo Cattrini, Giulia Buzzatti, et al.
Anti-Cancer Drugs|May 17, 2016
Immunotherapy for genitourinary cancer: state of the art and new perspectivesCarlo Cattrini, Chiara Dellepiane, Alessia Cavo, et al.
Cancers|April 12, 2022
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical ReviewCarlo Cattrini, Orazio Caffo, Ugo De Giorgi, et al.
Cancers|September 22, 2019
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer PatientsCarlo Cattrini, Alessandra Rubagotti, Linda Zinoli, et al.
Cancers|September 28, 2021
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate CancerCarlo Cattrini, Rodrigo España, Alessia Mennitto, et al.
Therapeutic Advances in Urology|July 22, 2021
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Immunotherapy|November 22, 2021
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysisSebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, et al.
Cancers|September 25, 2019
Current Treatment Options for Metastatic Hormone-Sensitive Prostate CancerCarlo Cattrini, Elena Castro, Rebeca Lozano, et al.
Translational Oncology|May 17, 2020
Integrative Analysis of Periostin in Primary and Advanced Prostate CancerCarlo Cattrini, Paola Barboro, Alessandra Rubagotti, et al.
Anti-Cancer Drugs|July 12, 2016
Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectivesCarlo Messina, Giulia Buzzatti, Chiara Dellepiane, et al.
Breast Cancer Research and Treatment|July 29, 2018
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trialsCarlo Messina, Carlo Cattrini, Giulia Buzzatti, et al.
Anti-Cancer Drugs|May 17, 2016
Immunotherapy for genitourinary cancer: state of the art and new perspectivesCarlo Cattrini, Chiara Dellepiane, Alessia Cavo, et al.
Cancers|April 12, 2022
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical ReviewCarlo Cattrini, Orazio Caffo, Ugo De Giorgi, et al.
Cancers|September 22, 2019
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer PatientsCarlo Cattrini, Alessandra Rubagotti, Linda Zinoli, et al.
Cancers|September 28, 2021
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate CancerCarlo Cattrini, Rodrigo España, Alessia Mennitto, et al.
Therapeutic Advances in Urology|July 22, 2021
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, et al.
Pageof 6